Delivered ~21% worldwide revenue growth, ~5% adjusted EBITDA margin, and positive cash from operating activities in the quarter Third Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $48.7 million, representing growth of 20.6% U.S. revenue of $46.4 million, representing growth of 21.2%Gross margin of 79.8%, representing an improvement of 75 basis pointsNet loss of $4.6 million, representing an improvement of 30.6% Positive adjusted EBITDA of $2.3 million ...

财务业绩更新 - 公司公布2025年第三季度财务业绩并修订2025年全年收入指引 [1] - 2025年第三季度总收入为2940万美元，较2024年同期的2870万美元增长3% [5] - 产品收入为2060万美元，服务及其他收入为890万美元，增长6% [5] - 来自Tablo耗材和服务的经常性收入为2110万美元，与去年同期基本持平 [5] 盈利能力指标 - 毛利润为1160万美元，较2024年同期的980万美元增长18% [6] - 毛利率为39.4%，相比2024年同期的34.3%有所提升 [6] - 非GAAP毛利率达到39.9%，相比2024年同期的36.4%提升3.5个百分点 [6][9] - 产品毛利率为45.7%，服务及其他毛利率为24.8%，均高于去年同期 [6] 运营费用与现金流 - 运营费用为2740万美元，较去年同期下降19% [7] - 研发费用为540万美元，销售和营销费用为1360万美元，一般行政费用为850万美元 [7] - 非GAAP运营费用为2210万美元 [8] - 季度现金使用量低于600万美元，期末现金及短期投资总额约为1.82亿美元 [9][10] 业绩展望 - 修订2025年收入指引至1.15亿至1.20亿美元，此前指引为1.22亿至1.26亿美元 [3][11] - 非GAAP毛利率指引维持不变，仍预计在高位30%的区间 [3][11] - 预计2025年现金使用量将低于5000万美元，相比2024年超过1亿美元的现金使用量显著改善 [3][11] 管理层评论 - 医院需求持续增长，得益于公司技术、专业知识和服务的临床、运营和财务效益 [4] - 几项原预计在2025年下半年完成的大型商机时间点有所推迟，现已进入销售流程最后阶段，预计将在第四季度及2026年初完成 [4]

ST. LOUIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received U.S. Food and Drug Administration 510(k) clearance for its latest generation robotic system, GenesisX™. GenesisX is the latest advance in endovascular surgical robotics, building upon the established benefits of Robotic Magnetic Navigation while significantly enhancing the accessibility of the technology for ...

Increased revenue by 128% year over year (YoY) to $1.8 million Appointed Beyond Air Board member Bob Goodman as Interim Chief Commercial Officer Raised $12.0 million in debt financing; proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September 30, 2025 Achieves certificate for Medical Device Single Audit Program (MDSAP) Updated fiscal year 2026 revenue guidance to $8 – $10 million Conference call at 4:30 p.m. ET today, November 10th GARDEN CITY, N.Y., Nov. 1 ...

Enovis (NYSE:ENOV) 2025 Conference November 10, 2025 02:45 PM ET Speaker1All right. Good afternoon, everyone. Thank you so much for joining us. My name's Danielle Antalffy. I'm the U.S. MedTech analyst here at UBS. Very lucky to have with us the Enovis team, Damien McDonald, CEO, Ben Berry, CFO, and of course, Kyle Rose, Head of Investor Relations. Maybe a good place to start, just what is Enovis? Damien, I'd love to hear you're getting settled into your role. What brought you to Enovis? What attracted you ...

New York, New York--(Newsfile Corp. - November 10, 2025) - If you suffered a loss on your Inspire Medical Systems, Inc. (NYSE: INSP) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/inspire-medical-systems-inc-lawsuit-submission-form?prid=176578&wire=5&utm_campaign=2or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareho ...

诉讼核心指控 - 公司在2024年7月26日至2025年9月17日期间被指控发布了 materially false and/or misleading statements [3] - 公司被指控未披露其对G6和G7血糖监测产品进行了未经美国食品药品监督管理局授权的重大设计变更 [3] - 上述设计变更导致G6和G7设备比之前的版本可靠性降低，对依赖其获取准确血糖读数的用户构成重大健康风险 [3] 产品问题细节 - 被告对G7设备在可靠性、准确性和功能性方面的改进宣传被指控为夸大其词 [3] - 被告被指控淡化了受影响的G7设备所引发问题的真实范围和严重性以及相关的健康风险 [3] 对公司的影响 - 上述问题使公司面临监管审查和执法行动加剧的风险，以及重大的法律、声誉和财务损害风险 [3] - 因此，被告在相关时间内的公开陈述被指控存在 materially false and/or misleading [3]

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Baxter International, Inc. (NYSE: BAX). Shareholders who purchased shares of BAX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/baxter-international-inc-loss-submission-form-2/?id=176105&from=3 CLASS PER ...

事件概述 - Rosen Law Firm正在调查Tandem Diabetes Care Inc (NASDAQ: TNDM) 可能向投资公众发布了重大误导性商业信息的指控，并准备代表股东提起证券集体诉讼 [1] - 该调查涉及公司因特定产品问题而可能产生的证券索赔 [1] 事件背景 - 2025年8月7日开盘前，Tandem Diabetes Care发布新闻稿，宣布对部分t:slim X2胰岛素泵进行自愿医疗器械纠正，以解决一个可能导致胰岛素输送中断的扬声器相关潜在问题 [3] - 受此消息影响，Tandem Diabetes Care的股价在2025年8月7日当日下跌19.9% [3] 律所信息 - Rosen Law Firm是一家在全球范围内代表投资者的律师事务所，专注于证券集体诉讼和股东派生诉讼 [4] - 该律所曾达成针对中国公司的史上最大证券集体诉讼和解，并因2017年达成的证券集体诉讼和解数量被ISS Securities Class Action Services评为第一名 [4] - 自2013年以来，该律所每年均位列前四名，已为投资者追回数亿美元，其中2019年即为投资者获得超过4.38亿美元 [4]

PresentationTimothy HerbertFounder, Chairman, CEO & President It was a very important quarter for us to report back, and there's so much tension that we had after the end of the second quarter, that was quite a challenging quarter for us, working through the transition from Inspire IV to our next-generation Inspire V system. We made tremendous progress with that during the third quarter, had a very good pickup that showed with our results as well. But most importantly is we are able to report the patient ou ...